Achtnichts, Lutz; Ovchinnikov, Arkady; Jakopp, Barbara; Oberle, Michael; Nedeltchev, Krassen; Fux, Christoph Andreas; Sellner, Johann; Findling, Oliver (2022). SARS-CoV-2 mRNA Vaccination in People with Multiple Sclerosis Treated with Fingolimod: Protective Humoral Immune Responses May Develop after the Preferred Third Shot. Vaccines, 10(2) MDPI 10.3390/vaccines10020341
|
Text
vaccines-10-00341-v2.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (472kB) | Preview |
Evidence suggests limited development of protective IgG responses to mRNA-based vaccines in sphingosine-1-phosphate receptor (S1PR)-modulator treated individuals with multiple sclerosis (MS). We studied the extent of the humoral immune response after the preferred third mRNA SARS-CoV-2 vaccine in S1PR-modulator treated people with MS (pwMS) and insufficient IgG responses after the standard immunization scheme. Eight pwMS that were treated with fingolimod received a third homologous SARS-CoV-2 mRNA vaccine dose, either the Moderna's mRNA-1273 or Pfizer-BioNTech's BNT162b2 vaccine. We quantified the serum levels of IgG antibodies against the receptor-binding domain of SARS-CoV-2 four weeks later. An antibody titer of 100 AU/mL or more was considered protective. After the third vaccination, we found clinically relevant IgG titers in four out of eight individuals (50%). We conclude that the humoral immune response may reach protective levels after the third preferred dose of the homologous SARS-CoV-2 mRNA vaccine. Vaccine shots in S1PR-modulator treated pwMS ahead of schedule may be a strategy to overcome insufficient humoral immune responses following the standard vaccination scheme.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Neurology |
UniBE Contributor: |
Nedeltchev, Krassen |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
2076-393X |
Publisher: |
MDPI |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
01 Mar 2022 12:29 |
Last Modified: |
05 Dec 2022 16:11 |
Publisher DOI: |
10.3390/vaccines10020341 |
PubMed ID: |
35214799 |
Uncontrolled Keywords: |
COVID-19 S1PR-modulator SARS-CoV-2 fingolimod humoral immune response vaccination |
BORIS DOI: |
10.48350/166125 |
URI: |
https://boris.unibe.ch/id/eprint/166125 |
Actions (login required)
 |
Edit item |